Sivik Global Healthcare LLC purchased a new position in shares of Qiagen N.V. (NASDAQ:QGEN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,000 shares of the company’s stock, valued at approximately $1,890,000.

A number of other large investors have also recently added to or reduced their stakes in QGEN. Acrospire Investment Management LLC raised its stake in shares of Qiagen N.V. by 11.7% in the second quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after acquiring an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Qiagen N.V. by 0.5% in the second quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after acquiring an additional 20 shares in the last quarter. Quadrant Capital Group LLC raised its stake in shares of Qiagen N.V. by 4.1% in the second quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after acquiring an additional 225 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of Qiagen N.V. in the second quarter valued at $211,000. Finally, Public Employees Retirement Association of Colorado raised its stake in shares of Qiagen N.V. by 3.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock valued at $242,000 after acquiring an additional 246 shares in the last quarter. Institutional investors own 59.96% of the company’s stock.

Several analysts have recently issued reports on QGEN shares. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Friday, July 28th. TheStreet cut Qiagen N.V. from a “b” rating to a “c+” rating in a research note on Thursday, July 27th. Deutsche Bank AG reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, July 31st. Jefferies Group LLC restated a “hold” rating and issued a $28.00 price target (up from $25.00) on shares of Qiagen N.V. in a research note on Monday, July 31st. Finally, Independent Research GmbH upgraded Qiagen N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $34.06.

ILLEGAL ACTIVITY NOTICE: “60,000 Shares in Qiagen N.V. (QGEN) Purchased by Sivik Global Healthcare LLC” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/24/60000-shares-in-qiagen-n-v-qgen-purchased-by-sivik-global-healthcare-llc.html.

Shares of Qiagen N.V. (QGEN) opened at $31.87 on Friday. Qiagen N.V. has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a quick ratio of 4.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $7,255.53, a price-to-earnings ratio of 25.91, a price-to-earnings-growth ratio of 1.95 and a beta of 1.13.

Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.32. Qiagen N.V. had a return on equity of 11.36% and a net margin of 6.40%. The company had revenue of $364.00 million for the quarter, compared to analysts’ expectations of $363.42 million. During the same period last year, the firm earned $0.29 earnings per share. Qiagen N.V.’s quarterly revenue was up 7.5% on a year-over-year basis. equities research analysts predict that Qiagen N.V. will post 1.25 EPS for the current year.

Qiagen N.V. Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).

Institutional Ownership by Quarter for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.